Swedbank AB grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 0.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,489 shares of the medical research company’s stock after acquiring an additional 786 shares during the quarter. Swedbank AB owned about 0.05% of IQVIA worth $21,680,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in IQV. Park Place Capital Corp purchased a new stake in IQVIA in the third quarter worth approximately $28,000. Rise Advisors LLC bought a new stake in shares of IQVIA in the first quarter worth $31,000. Versant Capital Management Inc increased its position in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Riverview Trust Co bought a new position in IQVIA in the first quarter valued at about $32,000. Finally, Opal Wealth Advisors LLC purchased a new position in IQVIA in the second quarter worth about $27,000. 89.62% of the stock is currently owned by institutional investors.
Insider Activity at IQVIA
In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.60% of the stock is owned by insiders.
Analysts Set New Price Targets
View Our Latest Stock Analysis on IQV
IQVIA Price Performance
NYSE:IQV opened at $233.06 on Thursday. The business’s 50-day moving average is $239.14 and its 200 day moving average is $231.33. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a market capitalization of $42.46 billion, a P/E ratio of 31.84, a P/E/G ratio of 2.18 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.
IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the firm posted $2.22 earnings per share. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
- Five stocks we like better than IQVIA
- Trading Stocks: RSI and Why it’s Useful
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Monster Growth Stocks to Buy Now
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.